Compare · HIND vs NVO
HIND vs NVO
Side-by-side comparison of Vyome Holdings Inc. (HIND) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIND and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.00B, about 15733.6x HIND ($11.4M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for HIND).
- NVO has more recent analyst coverage (25 ratings vs 1 for HIND).
- Company
- Vyome Holdings Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $11.4M
- $180.00B
- 1M return
- -
- +6.62%
- 1Y return
- -
- -17.28%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 2
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HIND
- SEC Form 10-Q filed by Vyome Holdings Inc.
- Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
- Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
- SEC Form 4 filed by Vyome Holdings Inc.
- Chardan Capital Markets initiated coverage on Vyome Holdings with a new price target
- SEC Form 3 filed by new insider Leonard Jerry
- Vyome Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Vyome Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
- SEC Form 10-Q filed by Vyome Holdings Inc.
Latest NVO
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S